Amino-oxyacetic acid as a palliative in tinnitus.
Amino-oxyacetic acid, previously shown to cause a reversible loss of hearing sensitivity and a reduction in endocochlear potential, was tried as a palliative in human tinnitus. Because the drug seemed to have a cochlear site of action, patients were selected for the study if their audiograms were indicative of cochlear lesions and if there was a reduction in tinnitus following intravenous lidocaine (lidocaine positive). Ten such patients received either 50 or 75 mg of amino-oxyacetic acid four times a day orally for one week or placebo administered in a random, crossover, double-blind design. Of these ten, three reported subjective lessening of tinnitus. One of those three and two others not reporting subjective lessening of tinnitus showed a substantial improvement in speech discrimination scores while receiving amino-oxyacetic acid but not placebo. One additional patient who did not receive lidocaine also reported a subjective lessening of tinnitus. Four patients who were lidocaine negative showed neither subjective nor objective improvement in tinnitus after treatment with amino-oxyacetic acid.
H T
HT
Reed
J
J
Meltzer
P
P
Crews
C H
CH
Norris
D B
DB
Quine
P S
PS
Guth
D000085:Acetates / Q000627:therapeutic use*; D000625:Aminooxyacetic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006311:Hearing Disorders / Q000150:complications; D006320:Hearing Tests; D006801:Humans; D008012:Lidocaine / Q000494:pharmacology; D008297:Male; D010166:Palliative Care; D011897:Random Allocation; D013067:Speech Perception; D014012:Tinnitus / Q000188:drug therapy* / Q000503:physiopathology
D000085:Acetates; D000625:Aminooxyacetic Acid; D008012:Lidocaine